Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. [electronic resource]
Producer: 20081006Description: 1304-8 p. digitalISSN:- 1523-4681
- Bone Density -- drug effects
- Bone Density Conservation Agents -- administration & dosage
- Bone and Bones -- drug effects
- Diphosphonates -- administration & dosage
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- HIV Infections -- physiopathology
- Humans
- Imidazoles -- administration & dosage
- Injections, Intravenous
- Male
- Middle Aged
- Placebos
- Time Factors
- Zoledronic Acid
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.